Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Reexamination Certificate
2007-02-20
2007-02-20
Badio, Barbara P. (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
C514S170000, C514S171000, C514S182000, C552S615000
Reexamination Certificate
active
10628057
ABSTRACT:
Novel estrogenic compounds of Formula I are provided.wherein the bond represented by the wavy line may be a single or double bond such that when the wavy line is a single bond, R1is selected from the group consisting of hydrogen, sulfate and glucoronate or other esters, and when the wavy line is a double bond, R1does not exist; R2is lower alkyl; R3may be selected from the group consisting of hydrogen, sulfate, or glucuronide or other esters; and R4through R13may independently be selected from the group consisting of hydrogen, hydroxy, ketone, lower allyl, lower alkoxy, halogen, and carbonyl groups and R14is selected from the group consisting of hydrogen, sulfate and glucoronide and other esters. When R1is hydroxy, the hydroxy or ester substituent may have either an α or a β orientation. Compositions of matter including compounds of the present invention are also provided as are methods of treating mammals in need of treatment using compounds of the present invention.
REFERENCES:
patent: 3230142 (1966-01-01), Spero
patent: 3487152 (1969-12-01), Carstensen et al.
patent: 3502772 (1970-03-01), Ijzerman
patent: 3568828 (1971-03-01), Lerner
patent: 3591688 (1971-07-01), Jones et al.
patent: 3639600 (1972-02-01), Hendrix
patent: 3733407 (1973-05-01), Segre
patent: 3795734 (1974-03-01), Rochefort
patent: 3813418 (1974-05-01), Hofmeister et al.
patent: 3836651 (1974-09-01), Rudel et al.
patent: 3932635 (1976-01-01), Segre
patent: 3939264 (1976-02-01), Lachnit-Fixson
patent: 3942641 (1976-03-01), Segre
patent: 3957982 (1976-05-01), Lachnit-Fixson et al.
patent: 3969502 (1976-07-01), Lachnit-Fixson
patent: 4027019 (1977-05-01), Shroff
patent: 4066757 (1978-01-01), Pasquale
patent: 4071623 (1978-01-01), van der Vies
patent: 4145416 (1979-03-01), Lachnit-Fixson et al.
patent: 4147783 (1979-04-01), van der Vies
patent: 4154820 (1979-05-01), Simoons
patent: 4210644 (1980-07-01), Ewing et al.
patent: 4259325 (1981-03-01), Prezewowsky et al.
patent: 4291028 (1981-09-01), Vorys
patent: 4292315 (1981-09-01), Vorys
patent: 4315925 (1982-02-01), Hussain et al.
patent: 4327725 (1982-05-01), Cortese et al.
patent: 4378356 (1983-03-01), De Jager
patent: 4383993 (1983-05-01), Hussain et al.
patent: 4390531 (1983-06-01), Edgren
patent: 4425339 (1984-01-01), Pitchford
patent: 4512986 (1985-04-01), Reel et al.
patent: 4530839 (1985-07-01), Pasquale
patent: 4544554 (1985-10-01), Pasquale
patent: 4616006 (1986-10-01), Pasquale
patent: 4621079 (1986-11-01), Lachnit-Fixson et al.
patent: 4628051 (1986-12-01), Pasquale
patent: 4738957 (1988-04-01), Laurent et al.
patent: 4756907 (1988-07-01), Beck et al.
patent: 4762717 (1988-08-01), Crowley, Jr.
patent: 4764378 (1988-08-01), Keith et al.
patent: 4783337 (1988-11-01), Wong et al.
patent: 4816257 (1989-03-01), Buster et al.
patent: 4816258 (1989-03-01), Nedberge et al.
patent: 4826831 (1989-05-01), Plunkett et al.
patent: 4855305 (1989-08-01), Cohen
patent: 4900734 (1990-02-01), Maxson et al.
patent: 4914089 (1990-04-01), Tax
patent: 4921843 (1990-05-01), Pasquale
patent: 4962098 (1990-10-01), Boissonneault
patent: 4977147 (1990-12-01), Jungblut et al.
patent: 5006345 (1991-04-01), Lang
patent: 5010070 (1991-04-01), Boissonneault
patent: 5043331 (1991-08-01), Hirvonen et al.
patent: 5089482 (1992-02-01), Hermens et al.
patent: 5098714 (1992-03-01), Wright et al.
patent: 5108995 (1992-04-01), Casper
patent: 5130137 (1992-07-01), Crowley, Jr.
patent: 5183814 (1993-02-01), Dukes
patent: 5200197 (1993-04-01), Wright et al.
patent: 5208225 (1993-05-01), Boissonneault et al.
patent: 5210081 (1993-05-01), Raveendranath et al.
patent: 5262408 (1993-11-01), Bergink
patent: 5276022 (1994-01-01), Casper
patent: 5280023 (1994-01-01), Ehrlich et al.
patent: 5288717 (1994-02-01), Raveendranath et al.
patent: 5362720 (1994-11-01), Labrie
patent: 5382573 (1995-01-01), Casper
patent: 5418228 (1995-05-01), Bennink
patent: 5434146 (1995-07-01), Labrie et al.
patent: 5464871 (1995-11-01), Kun et al.
patent: 5510342 (1996-04-01), Washburn et al.
patent: 5541172 (1996-07-01), Labrie
patent: 5545634 (1996-08-01), Labrie
patent: 5547948 (1996-08-01), Barcomb
patent: 5567695 (1996-10-01), Labrie
patent: 5629303 (1997-05-01), Labrie et al.
patent: 5654011 (1997-08-01), Jackson et al.
patent: 5753639 (1998-05-01), Labrie
patent: 5759576 (1998-06-01), Barcomb
patent: 5759577 (1998-06-01), Barcomb
patent: 5807586 (1998-09-01), Jackson et al.
patent: 5846960 (1998-12-01), Labrie
patent: 5861387 (1999-01-01), Labrie et al.
patent: 5861431 (1999-01-01), Hildebrand et al.
patent: 5908638 (1999-06-01), Huber et al.
patent: RE36247 (1999-07-01), Plunkett et al.
patent: 5998639 (1999-12-01), Raijmakers et al.
patent: 6040333 (2000-03-01), Jackson
patent: 2431694 (1976-03-01), None
patent: 2624025 (1976-12-01), None
patent: 3341638 (1983-11-01), None
patent: 1214712 (1970-12-01), None
patent: 1561244 (1980-02-01), None
patent: 2096462 (1982-10-01), None
patent: 25265 (1969-12-01), None
Andreolini, et al.,Estrogen Conjugates in Late-Pregnancy Fluids: Extraction and Group Separation by a Graphitized Carbon Black Cartridge and Quantification by High-Performance Liquid Chromatography, Anal. Chem. 59:1720-1725 (1987).
Fujino, et al.,3-(Difluoro-1.3.5-trianinyl)-1-(ethylthio)-2-n-propylbenz[f]isoindole as a Fluorescence Derivation Reagent for Estrogens in High-Performance Liquid Chromatography, Chem. Pharm. Bull., 37(7): 1939-1940 (1989).
Takadate, et al.,A Convenient Derivatization with Anion Exchange Resin Catalysts for High-Performance Liquid Chromatographic Analysis. I. Derivatization of Estrogens with Dansyl Chloride, Chem. Pharm. Bull., 33(11): 5092-5095 (1985).
Novakovic, et al.,High-Performance Liquid Chromatographic Determination of Equine Estrogens with Ultraviolet Absorbance and Electrochemical Detection, Journal of Chromatography A, 678: 359-363 (1994).
Townsend, et al.,High-Performance Liquid Chromatographic Determination of Conjugated Estrogens in Tablets, Journal of Chromatography, 450: 414-419 (1988).
Ishida, et al.,Determination of Oestrogens in Pregnancy Urine by High-Performance Liquid Chromatography with Fluorescence Detection, Journal of Chromatography, 431: 249-257 (1988).
Conjugated Estrogens, The United States Pharmacopcia (USP), published by United States Pharmacopeial Convention, Inc., pp. 627-629 (2000).
Synthetic Generic Conjugated Estrogens: Timeline, May 5, 1997, <http://www.fda.gov/cder
ews/cetimeline.htm>.
FDA Statement on Generic Premarin, HHS News Press Release, P97-12, May 5, 1997, <http://www.fda.gov/cder/cepressrelease.htm>.
New Drug Approval for Cenestin, Synthetic Conjugated Estrogens, A: Mar. 24, 1999,Questions and Answers, <http://www.fda.gov/cder
ews/cenestin/qa.htm>.
NDA 20-992 Cenestin™ (synthetic conjugated estrogens, A) Tablets Physicians Package Insert, pp. 1-10 (1999).
NDA 20-992 Cenestin™ (synthetic conjugated estrogens, A) Tablets Patient Package Insert, pp. 11-13 (1999).
FDA Backgrounder on Conjugated Estrogens, May 5, 1997, <http://www.fda.gov/cder/cebackground.htm>.
Letter from Yana Ruth Mille, Chief, Compendial Operations Staff, HFD-354, Office of Pharmaceutical Science, Center for Drug Evaluation & Research to Joseph G. Valentino, J.D., Senior Vice President and General Counsel, The United States Pharmacopeial Convention, Inc. (Mar. 8, 2000) (REF: 3-00-001-O).
Letter from Yana Ruth Mille, Chief, Compendial Operations Staff, HFD-354, Office of Pharmaceutical Science, Center for Drug Evaluation & Research to Joseph G. Valentino, J.D., Senior Vice President and General Counsel, The United States Pharmacopeial Convention, Inc. (Mar. 8, 2000) (REF: 3-00-002-O).
Memorandum from Janet Woodcock, M.D., Director, Center for Drug Evaluation & Research to Douglas L. Sporn, Director, Office of Generic Drugs, regarding Approvability of a Synthetic Generic Version of Premarin (May 5, 1997).
Sakac, Marijan N. et al., “Chemical Behavior of 3, 17.beta.-dipropionoxy-9.alpha.-hydroxyestra-1,3,5(10)-trien-6-one,”Database Chemabs 'Online!, Database accession No. 128:180573
Hill Edward N.
Sancilio Frederick D.
Whittle Robert R.
Badio Barbara P.
Barr Laboratories, Inc.
Myers Bigel Sibley & Sajovec P.A.
LandOfFree
(3) and (6) substituted estrogenic compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with (3) and (6) substituted estrogenic compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and (3) and (6) substituted estrogenic compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3821461